Pemigatinib for Myeloid/Lymphoid Neoplasms with <i>FGFR1</i> Rearrangement
In our study, pemigatinib manifested near complete efficacy in chronic-phase patients with MLN-<i>FGFR1</i>, while the complete response rate was close to 50% in blast-phase patients. Toxicities were manageable with dose modifications. (Funded by Incyte Corporation; FIGHT-203 ClinicalTrials.gov number, NCT03011372.).
Authors
- Stephen T. Oh (ORCID: https://orcid.org/0000-0002-8564-5400)
- Françoise Huguet (ORCID: https://orcid.org/0000-0002-9576-8578)
- Jean‐Jacques Kiladjian (ORCID: https://orcid.org/0000-0002-8121-438X)
- Tracy I. George (ORCID: https://orcid.org/0000-0001-5478-7847)
- Aidan G. Gilmartin
- Kensuke Usuki (ORCID: https://orcid.org/0000-0002-1216-4470)
- Andreas Reiter (ORCID: https://orcid.org/0000-0002-7718-6507)
- Hui‐Ling Zhen (ORCID: https://orcid.org/0000-0003-0310-3825)
- Jay Patel (ORCID: https://orcid.org/0000-0001-6531-3225)
- Alessandro Maria Vannucchi (ORCID: https://orcid.org/0000-0001-5755-0730)
- Claire N. Harrison (ORCID: https://orcid.org/0000-0002-3212-920X)
- Alessandro Rambaldi (ORCID: https://orcid.org/0000-0002-3739-7502)
- Jason Gotlib (ORCID: https://orcid.org/0000-0001-8253-6156)
- Juan Carlos Hernández‐Boluda (ORCID: https://orcid.org/0000-0002-4289-3113)
- Philomena Colucci
- Ellen K. Ritchie (ORCID: https://orcid.org/0000-0001-8150-5542)
- William E. Shomali (ORCID: https://orcid.org/0000-0001-6500-350X)
- Srđan Verstovšek (ORCID: https://orcid.org/0000-0002-6912-8569)
- Luke P. Akard
- Cheryl Langford
- Natália Oliveira (ORCID: https://orcid.org/0009-0006-1941-0925)
Institutions
- The University of Texas MD Anderson Cancer Center (US)
- Universitat de València (ES)
- University of Milan (IT)
- Guy's and St Thomas' NHS Foundation Trust (GB)
- Washington University in St. Louis (US)
- Université Paris Cité (FR)
- Cornell University (US)
- Heidelberg University (DE)
- Huntsman Cancer Institute (US)
- Saint Louis University Hospital (US)
- University Hospital Heidelberg (DE)
- Hospital Clínico Universitario de Valencia (ES)
- Presbyterian Hospital (US)
- Teikyo University Hospital (JP)
- Institut universitaire du cancer de Toulouse Oncopole (FR)
- Franciscan Health Indianapolis (US)
- Ospedale Papa Giovanni XXIII (IT)
- Azienda Ospedaliero-Universitaria Careggi (IT)
- Stanford Medicine (US)
- University Medical Centre Mannheim (DE)
- Teikyo University (JP)
- Incyte (United States) (US)
- Stanford University (US)
Publication Details
- Journal
- NEJM Evidence
- Published
- 2025-08-26
- DOI
- https://doi.org/10.1056/evidoa2500017
- Citations
- 6
- Primary Topic
- Eosinophilic Disorders and Syndromes
- Type
- article
- Field-Weighted Citation Impact
- 10.01